![[刘小婷]](https://staticres.ablesci.com/avatar/u/b901337a524b2f8aa312b155bd115e5c.png?v=5b0f)
Lv61
2070 积分 2022-09-21 加入
Secreted CLCA1 modulates TMEM16A to activate Ca2+-dependent chloride currents in human cells
5天前
已完结
Emerging Concepts and Therapies for Mucoobstructive Lung Disease
6天前
已完结
The pharmacology of the TMEM16A channel: therapeutic opportunities
6天前
已完结
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
2个月前
已完结
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
2个月前
已完结
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
3个月前
已完结
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity
3个月前
已完结
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes
3个月前
已完结
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity
3个月前
已完结
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity
3个月前
已完结
皖公网安备34019202002308
